We need to readjust the way we educate physicians. Young doctors need to understand money more clearly from the start (especially the $200,000 in school loans part). But they must also grasp the hypocrisy that tells them that medical businesses, like Pharma, are inherently evil.
Recent reports illuminate a growing black market trade in blood from Ebola survivors. Those with the desire and resources are buying blood in hopes of curing current infections or stockpiling for future infections.
The history of psychiatry is a history of fad diagnoses that come out of nowhere to capture much more attention than they deserve. Current fads are distinguished only by the billions of dollars spent by powerful commercial forces to create and push them.
Forget everything you've heard about the benefits of Tamiflu, the Roche corporation's blockbuster influenza drug. A new analysis that includes previously-unpublished trials offers a fresh, and very unflattering, perspective.
Simply to dismiss the private sector out of hand would be a mistake for the global public health field. Private companies play a pivotal role in public health issues. It is only through a marriage of the public and the private that we can see effective change in health issues across the globe.
It was not a great surprise that the FDA's new cephalosporin livestock rules have the Agribusiness Seal of Approval. It was Big Pharma and Agribusiness lobbying that killed its stronger cephalosporin rules issued four years after.
It used to be joked that a consultant is someone who borrows your watch to tell you what time it is. These days, the opportunist is Big Pharma, which raises your insurance premiums and taxes while providing you "low-priced" drugs that you paid for.
So far in this election cycle, the only vaguely relevant recognition of the importance of leadership in biotechnology for the country's future was a polemical and uninformative exchange on vaccination policy.
A number of NGOs working on public health issues are concerned that the President may push India to adopt more strict intellectual property protections on pharmaceutical drugs. They have reasons to be concerned.